Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.

Kaipio K, Chen P, Roering P, Huhtinen K, Mikkonen P, Östling P, Lehtinen L, Mansuri N, Korpela T, Potdar S, Hynninen J, Auranen A, Grénman S, Wennerberg K, Hautaniemi S, Carpén O.

J Pathol. 2019 Oct 9. doi: 10.1002/path.5356. [Epub ahead of print]

PMID:
31595974
2.

Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.

Liebscher CA, Prinzler J, Sinn BV, Budczies J, Denkert C, Noske A, Sehouli J, Braicu EI, Dietel M, Darb-Esfahani S.

Hum Pathol. 2013 Aug;44(8):1465-71. doi: 10.1016/j.humpath.2012.12.016. Epub 2013 Mar 1.

PMID:
23465277
4.

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.

Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2010 Dec;9(12):3186-99. doi: 10.1158/1535-7163.MCT-10-0563. Epub 2010 Oct 1.

5.

Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.

Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X.

J Ovarian Res. 2017 Feb 10;10(1):9. doi: 10.1186/s13048-017-0304-9.

6.

Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma.

Roy M, Connor J, Al-Niaimi A, Rose SL, Mahajan A.

Hum Pathol. 2018 Mar;73:1-6. doi: 10.1016/j.humpath.2017.06.025. Epub 2017 Aug 26.

PMID:
28851663
7.

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.

Norris EJ, Zhang Q, Jones WD, DeStephanis D, Sutker AP, Livasy CA, Ganapathi RN, Tait DL, Ganapathi MK.

J Pathol. 2019 Jul;248(3):352-362. doi: 10.1002/path.5264. Epub 2019 May 14.

8.

Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines.

Januchowski R, Wojtowicz K, Sterzyſska K, Sosiſska P, Andrzejewska M, Zawierucha P, Nowicki M, Zabel M.

Int J Biochem Cell Biol. 2016 Sep;78:248-259. doi: 10.1016/j.biocel.2016.07.017. Epub 2016 Jul 19.

PMID:
27443528
9.

GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.

Chen HJ, Huang RL, Liew PL, Su PH, Chen LY, Weng YC, Chang CC, Wang YC, Chan MW, Lai HC.

Int J Cancer. 2018 Dec 15;143(12):3106-3119. doi: 10.1002/ijc.31750. Epub 2018 Oct 3.

PMID:
30006927
10.

γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.

Li Y, Wu T, Wang Y, Yang L, Hu C, Chen L, Wu S.

Gynecol Oncol. 2018 Apr;149(1):163-172. doi: 10.1016/j.ygyno.2018.01.023. Epub 2018 Feb 9.

PMID:
29429592
11.

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.

Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA.

BMC Cancer. 2013 Nov 16;13:549. doi: 10.1186/1471-2407-13-549.

12.

Prognostic value of GRIM-19, NF-κB and IKK2 in patients with high-grade serous ovarian cancer.

Ilelis F, do Amaral NS, Alves MR, da Costa AABA, Calsavara VF, Lordello L, De Brot L, Soares FA, Rodrigues IS, Rocha RM.

Pathol Res Pract. 2018 Feb;214(2):187-194. doi: 10.1016/j.prp.2017.12.002. Epub 2017 Dec 6.

PMID:
29254797
13.

[Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].

Mao YN, Zeng LX, Li YH, Liu YZ, Wu JY, Li L, Wang Q.

Zhonghua Fu Chan Ke Za Zhi. 2017 Oct 25;52(10):687-696. doi: 10.3760/cma.j.issn.0529-567X.2017.10.008. Chinese.

PMID:
29060967
14.

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.

Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, Ellul J, Kleinschmidt M, Kinross KM, Bowtell DD, Christensen JG, Hicks RJ, Johnstone RW, McArthur GA, Hannan RD, Phillips WA, Pearson RB.

Eur J Cancer. 2013 Dec;49(18):3936-44. doi: 10.1016/j.ejca.2013.08.007. Epub 2013 Sep 3.

PMID:
24011934
15.

ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.

Meng E, Mitra A, Tripathi K, Finan MA, Scalici J, McClellan S, Madeira da Silva L, Reed E, Shevde LA, Palle K, Rocconi RP.

PLoS One. 2014 Sep 12;9(9):e107142. doi: 10.1371/journal.pone.0107142. eCollection 2014.

16.

Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.

Chung YS, Lee JY, Kim HS, Nam EJ, Kim SW, Kim YT.

Yonsei Med J. 2018 Oct;59(8):930-936. doi: 10.3349/ymj.2018.59.8.930.

17.

A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer.

Nwani NG, Condello S, Wang Y, Swetzig WM, Barber E, Hurley T, Matei D.

Cancers (Basel). 2019 Apr 8;11(4). pii: E502. doi: 10.3390/cancers11040502.

18.

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA.

Br J Cancer. 2015 Mar 31;112(7):1215-22. doi: 10.1038/bjc.2015.81. Erratum in: Br J Cancer. 2015 Dec 22;113(12):1746. Masson, A-M M [corrected to Mes-Masson, A-M].

19.

Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.

Dahl ES, Buj R, Leon KE, Newell JM, Imamura Y, Bitler BG, Snyder NW, Aird KM.

Mol Cancer Res. 2019 Aug;17(8):1710-1720. doi: 10.1158/1541-7786.MCR-18-1233. Epub 2019 May 20.

PMID:
31110157
20.

Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF signalling in MCF-7 breast cancer cells.

Ciccone V, Terzuoli E, Donnini S, Giachetti A, Morbidelli L, Ziche M.

J Exp Clin Cancer Res. 2018 Dec 12;37(1):311. doi: 10.1186/s13046-018-0975-0. Erratum in: J Exp Clin Cancer Res. 2019 Feb 1;38(1):45.

Supplemental Content

Support Center